ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma

Inclusion Criteria: * Participant has fully understood the trial, agrees to comply with the study treatment regimen and visit schedule, and voluntarily signs the informed consent form (ICF). * Male or female participants aged 18 to 75 years (inclusive) at the time of signing the informed consent form (ICF). * Life expectancy of more than 3 months. * Histologically confirmed recurrent or metastatic neuroendocrine carcinoma (NEC). * The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1. Exclusion Criteria: * History, computed tomography (CT), or magnetic resonance imaging (MRI) findings suggestive of central nervous system (CNS) metastases or leptomeningeal metastases.